ESC Professional Premium Access

Atrial fibrillation: rate or rhythm control

Event: ESC Congress 2022
Topic: Rate Control
Session type: Moderated ePosters
Date: 29 August 2022
Time: 15:15 - 15:55

Congress Session

6 presentations in this session

Association between early rhythm control and the risk of dementia in patients with atrial fibrillation and prior history of stroke: a nationwide population-based study

Speaker: Doctor S. Lee (Seoul, KR)
Thumbnail

Effect of dronedarone versus placebo on atrial fibrillation progression: a post-hoc analysis from ATHENA trial

Speaker: Professor C. Blomstrom-Lundqvist (Orebro, SE)
Thumbnail

Dronedarone versus sotalol in patients with atrial fibrillation: a systematic literature review and network meta-analysis

Speaker: Professor J. Camm (London, GB)
Thumbnail

Holistic approach of ablation versus antiarrhythmic drugs for efficacy, safety, and quality of life improvement in rhythm control of atrial fibrillation: a meta-analysis of randomized trials

Speaker: Mr G. Prana Jagannatha (Denpasar, ID)
Thumbnail

Sex differences in the use of rhythm control strategies in patients with atrial fibrillation in FinACAF study

Speaker: Ms K. Kalatsova (Helsinki, FI)
Thumbnail

Prevalence of modifiable risk factors and related poor cardiovascular outcomes following atrial fibrillation ablation

Speaker: Doctor K. Stout (Omaha, US)
Thumbnail

6 speakers from this session

Doctor So-Ryoung Lee

Seoul National University Hospital, Seoul (Korea (Republic of))
0 follower

Professor Carina Blomstrom-Lundqvist

Orebro University Hospital, Orebro (Sweden)
27 presentations
3 followers

Professor John Camm

St George's University of London, London (United Kingdom of Great Britain & Northern Ireland)
55 presentations
1 follower

Mr Gusti Ngurah Prana Jagannatha

Udayana University, Denpasar (Indonesia)
0 follower

Ms Ksenia Kalatsova

University of Helsinki, Helsinki (Finland)
0 follower

Doctor Kara Stout

University of Nebraska Medical Center, Omaha (United States of America)
0 follower

This platform is supported by

logo Novo Nordisk